[Clinical trial of a combination of human lymphoblastoid interferon (HLBI) and methyl-prednisolone (HLBI-mP) in multiple myeloma].
Two previously treated patients with multiple myeloma were given combination therapy of daily HLBI (3-6 x 10(6) I.U/day) and methyl-prednisolone pulse (250 mg/day). A 77-year-old patient with IgG-kappa myeloma achieved a complete remission, although the initial general condition was poor. The other 59-year-old patient with IgA-lambda myeloma, which had become resistant to previous chemotherapy including VAD, achieved partial remission. Mild myelosuppression and hepatotoxicity were the only side effects observed, and they disappeared upon discontinuation of the drug.
Fukuzawa
Y
Y
Chubu Rosai Hospital, Nagoya University.
Kawamura
T
T
Ohno
R
R
D000368:Aged; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D012074:Remission Induction
D007370:Interferon Type I; D008775:Methylprednisolone